Expansion of Umbilical Cord Blood Using a Unique Bio-system
|ClinicalTrials.gov Identifier: NCT01061879|
Recruitment Status : Completed
First Posted : February 3, 2010
Last Update Posted : January 3, 2013
By doing this study, researchers hope to develop a special technique and laboratory conditions to help support umbilical stem cell growth and multiplication.
In this project, researchers propose a three dimensional (3D) microenvironment that mimics the bone marrow stem cell microenvironment, with its supporting cells of osteoblasts and stromal cells. In theory, this will result in better expansion of cord blood stem cells ex vivo.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Ex Vivo Expansion of Umbilical Cord Blood Using a Unique Bio-system|
|Study Start Date :||February 2010|
|Primary Completion Date :||November 2010|
|Study Completion Date :||November 2010|
- bio-system for ex-vivo expansion of umbilical cord blood stem cells [ Time Frame: one year ]To successfully expand the umbilical cord blood stem cells, a microenvironment that resembles the stem cell microenvironment, or stem cell 'niche' should be created. In designing this bio-system, we make use of several observations. Firstly, bone osteoblasts are important in promoting hematopoietic stem cell expansion , accordingly, this bio-system will ensure the physical proximity of the cord blood stem cells to a 3D bone tissue derived from mesenchymal stem cells (MSCs). These MSCs will be isolated from Wharton's jelly, and by using an osteogenic medium and special scaffolds, these MSCs will differentiate into osteogenic progenitors creating a 3D bone structure . The other observation is that, co-culture of cord blood stem cells with mesenchymal stem cells is superior to liquid cultures in terms of ex vivo expansion , accordingly, in this experiment, undifferentiated MSCs will be co-cultured with cord blood stem cells in the created 3D bone structure.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01061879
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|Principal Investigator:||Omar Aljitawi, MD||University of Kansas Medical Center|